Biotech dealmaking is accelerating as major drugmakers face patent expirations and seek growth, focusing on five key therapeutic areas: radiopharmaceuticals, next-gen GLP-1, autologous CAR-T, allogeneic cell therapy, and antibody-drug conjugates (ADC). Leading publicly traded companies in these sectors include Lantheus (radiopharmaceuticals), Viking Therapeutics (next-gen GLP-1), Legend Biotech (autologous CAR-T), Allogene Therapeutics (allogeneic CAR-T), and ADC Therapeutics (ADCs). Each company shows strong standalone fundamentals with potential for mergers and acquisitions, though risks vary from clinical trial outcomes to financial challenges. Investors are advised to consider position sizing carefully due to the volatile nature of biotech stocks.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Inseego Corp. will release its financial results for the second quarter of 2026 on August 5, after market close. The company will hold a conference call the same day to discuss the results and business outlook. Investors can access the earnings repor...
Dyadic International has expanded its bio-industrial pipeline with a new proprietary enzyme program focused on advanced cellulose processing, building on the success of its EN3ZYME™ product. This initiative leverages Dyadic's Dapibus™ platform to str...
